a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CPTMatt: $300M in tradeable vouchers,
...Is very, very SIGNIFICANT FOR THIS LITTLE MICROCAP AND THE PEDIATRIC CANCER PATIENTS WHO’s LIVES MAY DEPEND UPON BREAKTHROUGH IN SCIENCE THAT CLRB HAS BUTTONED DOWN WITH DOZENS OF PATENTS IN THE USA AND JAPAN.
I AGREE WITH YOU THAT CLRB WILL LIKELY KEEP THE VOUCHERS FOR ITS OWN DEVELOPMENT REGULATORY APPROVAL, OR, AT WORST SELL ONE FOR A HUNDRED MILLION OR MORE DOLLARS TO PAY FOR COMPLETION OF ITS ONGOING CLINICAL TRIALLS AND FDA APPROVAL OF ITS SEVERAL PRODUCTS.
IF CRAMER WERE HE, HE MIGHT SAY AT THIS POINT: buy, Buy, BUY!!!
From Globe Newswire. PR OF TODAY:
“...Last month, Cellectar announced that the FDA also granted RPDD for CLR 131 for the treatment of neuroblastoma. If CLR 131 is approved by the FDA for either neuroblastoma or rhabdomyosarcoma, the rare pediatric disease designation may enable Cellectar to receive a priority review voucher. Priority review vouchers can be used by the sponsor to receive priority review for a future NDA or BLA submission, which would reduce the FDA review time from 12 months to six months. Currently, these vouchers can also be transferred or sold to another entity. Over the last 16 months, five priority review vouchers were sold for between $110 million to $150 million each. ”...
I agree bob wins!!!
I like this part of your PR too, since there are tens of thousands of little kids and their families looking for medical help in saving their lives:
“...The FDA grants RPDD for diseases that primarily affect children from birth to 18 years old, and affect fewer than 200,000 persons in the U.S. This program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.”...
IF IT WORKS AS A MARKER, IT WORKS
AS A “CURE”, IMHO!!!
The science is the same; can’t you see that?
WATCH THE CLINICAL TRIAL PHASE 2 NEWS RELEASES LATER THIS YEAR!
Company says there is FDA verifiable
merit in CLR131 AND MUCH MUCH MORE TO COME FOR CLRB!!!
THIS COMMOM STOCK, IMHO, IS A HUNDRED TIMES UNDER VALUED! WHO TOLD ME? A LITTLE “BLUEBIRD”.
Yes, they know how to play,
But how long until they do not have to play that game, because share demand spikes up on clinical trial news- great news for patients and investors?
Previously you estimated another year or so? They can burn mucho cash, right. This year 2018, CLRB WILL HAVE 2 or 3 clinical trials recruiting and administering 2 or 3 products. RESULTS?
Not in 2018...CLR 131 could be the first, if only diagnostically, to offer actual profits in 2020?
So when will greed succeed in supporting CLRB share price: mid-2019?
THAT WOULD BE AFTER THE RS GAME IS OVER A THIRD TIME...BUT HEY THAT IS WHAT COMMON SHARES ARE FOR WITHOUT A WHITE KNIGHT VC COMPANY OR A FAT ASS MERGER PARTNER!!!
What say you, Koly, on such a timeline and most likely fuel source for cash burn?
Possible “time to buy moment”,
...On low volume dip.
Then again, maybe not.
PASS THE CRYSTAL BALL, PLEASE!
Neither can we wait until the last minute to get the money
..:For our common Shares???
We need to stay in “Dollarland”.
But gravity here is ruthless...without startling good news.
17 million common shares outstanding 5-7-18,
https://ih.advfn.com/p.php?pid=nmona&article=77407873
...With another million plus shares to issue on the annual shareholder vote coming up.
18 million shares is not too many if the clinical trials end up well and end in 2018.
Folks would want in then, not out like now.
LOL
Someone has been accumulating CLRBZ warrants
For several weeks now. They are cheaper than CLRB common stock shares.
And more dangerous... but an interesting way for an insider to profit?
Shareholder annual meeting coming up soon.
I voted against “Big D”...share price is too low already!
Cramer might say just about here: BUY, BUY, BUY!!!
Of course he doesn’t say anything about “penny stocks”.
FINALLY, some hard news worth something!
May 9, 2018 4:00 PM ET ...Cellectar Biosciences,... (CLRB)
The FDA designates Cellectar Biosciences' (CLRB +3.6%) CLR 131 an Orphan Drug for the treatment of rhabdomyosarcoma, a rare pediatric soft tissue cancer.
Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
https://ih.advfn.com/p.php?pid=nmona&article=77387006
RUN SHORTY, RUN!!!
Our BOTS were just in high school
When the VIX hit them like puberty.
Hope they wise up soon!
And so it is written,
And so it shall be. RIP...
THE GREY FLANNEL SUIT ...ALL BUT FORGOTTEN.
Then, SELL, SELL, SELL!,,
I may buy your shares for future gain- long term gains under IRS Rules. Haha
Good luck in any Event!
CTs going GREAT, and
Insider trades in CLRBZ are reflecting this reality:
WAKE UP MS. Market !!!!!!
RIGHT, some one needs to call WATSON
AND find out what is wrong with this company. Block chain is not likely to rescue it with all the BC competition.
MAYBE A GOOD OLD FASHION MONOPOLY ON SOME INNOVATION WOULD SAVE IT,
THIS DOG NEEDS TO BARK...
AHEAD OF NEXT YEAR’s RALLY to $25 pps ON THE CLINICAL TRIALS NEWS.
THERE SHOULD BE SOME LEAKS THIS YEAR!
;))
Yep, another year of this hell.
EVERYONE WILL BE BROKE BY THEN.
Interesting 10-K release tonight:
They still have $10 M to finish clinical trials etc., including FDA Approved Trial on up to 30 children with various cancers THAT STARTS NEXT MONTH OR SO (2nd quarter 2018):
“...The FDA previously accepted our IND application for a Phase 1 open-label, dose-escalating study to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin’s lymphoma) and malignant brain tumors. We expect to initiate this study during the second quarter of 2018...”
https://ih.advfn.com/p.php?pid=nmona&article=77003902
Looks like ET lunchtime rally started,
And I wonder if it will be enough this week for a SHORT SQUEEZE ?
“They also serve who.......
ONLY STAND AND WAIT” -John Milton
https://en.m.wikipedia.org/wiki/When_I_Consider_How_My_Light_is_Spent
;))
Seeking Alpha today after hours:
“Thinly traded nano cap Cellectar Biosciences (NASDAQ:CLRB) is up 9% after hours on increased volume in response to the FDA designating PET imaging agent CLR 124 (18-(p-[131]-iodophenyl)octadecyl phosphocholine) an Orphan Drug for neuroblastoma , a cancer that develops from immature nerve cells.
Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved...”
ONE OF THESE DAYS, THE SHORTS WILL NOT BE ABLE TO CONTAIN CLRB.
UNTIL THEN, JUST BLINDLY STAND AND WAIT.
WELL I READ TODAY’s 8-K and
it is not much new....it just tells the SEC (and the public all at once) how broad and truly scientific the CLR131 Phase II Clinical Trial has become. There were no efficacy results published yet!
But today’s extended hour trading (on low volume) price gains seem out of proportion to the actual news (8-K) so, I still wonder if there is a private leak of initial Phase II results. And those are the buyers- especially the late day regular trading and during extended hours!
REMEMBER THE CLR131 TREATMENTS ONLY TAKE ONE OR TWO DAYS TO INFUSE, THE THE REST IS “WAIT AND SEE” HOW THE BLOOD TESTS GO OVER TIME. I BELIEVE WE ARE INTO A FEW MONTHS POST INFUSIONS ON SOME/A FEW VERY SICK- refractory patients. THE LONGER THEY LIVE, ON AVERAGE, THE MORE EXCITING IS GETS FOR THE PATIENTS AND THE STOCK PRICE.
IT IS ALL ABOUT THE DIFFERENT MEASURES OF EFFICACY/EFFECTIVENESS.
GOOD NEWS IS COMING NEXT WEEK.
Wait & see....
Or trade CLRB WARRNTS like
CLRBZ.
Thanks! That’s a critical system enhancement at a serious time of Korean Saber-Rattling.
I was impressed with IBM’s CEO when she was interviewed by CNBC at Davos. She was one of a few chairpersons selected for that economic summit. But she needs to do more innovation than Watson I.e. AIEQ ETF.
The bots were hung over today and
...This ETF underperformed a lively market. Hope they are on the wagon tonight!
Sunofwolf: 1.3 million volume is remarkable, but
...Price movement was rather calm. Still, I wonder what provoked this accumulation.
Hoping it was a leak of positive clinical trial data, but could have been market makers reloading.
We’ll see, as the President of the United States is fond of saying.
Thanks, Bob. Winning is closer than ever! ;))
Loaded the truck yesterday
with AIEQ shares. It is looking good so far...which ain’t FAR.
Up .50% already in hour two- go bots!
AIEQ website:
http://www.equbotetf.com/fund/
Hope the bots are not
Russian.
Up over 10 cents so far today,
Bots are working hard!
OLD BLUE’S chart is mostly blue today on volume indicator.
Last 8k is very positive: “...· The company expects revenue growth and margin stabilization in 2018.
· The company expects year-to-year revenue growth in the first quarter of 2018 versus 2017, at both current spot rates and constant currency, with growth rates relatively consistent with the fourth quarter of 2017.
· In the services segments, in both GTS and GBS, the projected revenue from the current backlog points to an improved revenue trajectory in 2018 versus 2017.
· For 2018, the company expects the GAAP tax rate to be approximately 2 points lower than the operating (non-GAAP) tax rate expectation. The company expects its operating (non-GAAP) tax rate for 2018 to be 16%, plus or minus 2 points (excluding discrete items), which is a 4 point headwind year to year. The tax rates reflect the implementation of U.S. tax reform, which includes a lower U.S. corporate tax rate, offset by the broader tax base and reduced foreign tax credit utilization.
· The company expects GAAP earnings per share from continuing operations for 2018 to be at least $11.70. Excluding acquisition-related charges of $0.78 per share and non-operating retirement-related items of $1.32 per share, operating (non-GAAP) earnings per share is expected to be at least $13.80.
· For the first quarter of 2018, the company expects operating (non-GAAP) earnings per share to be approximately 17 percent to 18 percent of the full-year expectation, which is consistent with the average first-quarter skew over the last 5 years.
· In each of the first quarters of 2017 and 2016, the company had a benefit from a discrete item. The company expects a potential benefit again in the first quarter of 2018, and as in the past, will likely take actions that will offset some portion of the benefit. This is reflected in the first-quarter skew expectations.
· Two of the accounting changes (revenue recognition and pension cost) that are effective for the company beginning January 1, 2018 are expected to essentially offset each other within the $13.80 full-year 2018 operating (non-GAAP) earnings per share expectation.
· The company expects free cash flow to be approximately $12 billion in 2018. Free cash flow realization, which is defined as free cash flow to income from continuing operations (GAAP), is expected to be well over 100%.
· 2018 free cash flow expectations include a year-to-year headwind from strong receivables collections in the fourth-quarter 2017, an approximate $600 million year-to-year headwind from cash tax payments and some growth in capital expenditures....”
HAPPY HOUR is clearly over with a “thud”.
IRONIC: QCOM brags it’s board is better than Broadcom’s
proposed Slate of Directors, then the EU fines QCOM over a Billion dollars for Qcom’s BAD BUSINESS PRACTICES.. . THAT DOES NOT SOUND LIKE A “WORLD CLASS” BOARD OF DIRECTORS TO ME. I VOTED THE BLUE PROXY SHEET THAT CAME IN THE MAIL!
https://www.cnbc.com/2018/01/24/the-associated-press-eu-fines-qualcomm-for-paying-apple-to-use-its-microchips.html
Nice bounce back today!
Well, I voted on the annual meeting proxy fight
Scheduled for this March!
Looks like QCOM was late in getting out the “White” proxy voting cards.
The blue cards from Broadcom arrived a week age....
Hint, hint....
Reply: calling Celgene, calling Celgene! Do you copy Celgene?